The accumulation of mutations in somatic cells have been implicated as a cause of ageing since the 1950s 1,2 . Yet, attempts to establish a causal relationship between somatic mutations and ageing have been constrained by the lack of methods to directly identify mutational events in primary human tissues. Here we provide detailed, genome-wide mutation frequencies and spectra of human B lymphocytes from healthy individuals across the entire human lifespan, from newborns to centenarians, using a recently developed, highly accurate single-cell whole-genome sequencing method 3 . We found that the number of somatic mutations increases from <500 per cell in newborns to >3,000 per cell in centenarians. We discovered mutational hotspot regions, some of which, as expected, located at immunoglobulin genes associated with somatic hypermutation. B cell-specific mutation signatures were observed associated with development, ageing or somatic hypermutation (SHM). The SHM signature strongly correlated with the signature found in human chronic lymphocytic leukemia and malignant B-cell lymphomas 4 , indicating that even in B cells of healthy individuals the potential cancer-causing events are already present. We also identified multiple mutations in sequence features relevant to cellular function, i.e., transcribed genes and gene regulatory regions. Such mutations increased significantly during ageing, but only at approximately half the rate of the genome average, indicating selection against mutations that impact B cell function. This first full characterization of the landscape of somatic mutations in human B lymphocytes indicates that spontaneous somatic mutations accumulating with age can be deleterious and may contribute to both the increased risk for leukemia and the functional decline of B lymphocytes in the elderly.
cell and validated the procedure by comparing mutations identified from SCMDA-amplified single cells with unamplified DNA from clones of the same cell population 3 .
Here, we used SCMDA to assess mutation accumulation as a function of age in human B lymphocytes from healthy individuals varying in age from 0 (newborns) to over 100 years (centenarians) . Mutation accumulation in these cells could be a causal factor in both the age-related increase in the incidence of B cell leukemia 9 and the observed age-related functional decline, such as loss of B cell activation 10 . We sequenced the genome of 56 single B lymphocytes and that of their corresponding 14 bulk DNAs using the remaining PBMCs (Methods; Supplementary Figs. 1,  2) . The average sequencing depth across the genome was 27.9±2.9 (s.d.) and 25.3±2.3 for the single cells and bulk DNAs, respectively. For single cells 51.4±4.7 % of the genome was covered at a depth of ≥ 20X; For bulk DNAs this was 78.6±5.1 % (Supplementary Table 1 ; Methods). Somatic SNVs in single cells were identified at a depth of ≥ 20X using SCcaller, a software tool developed specifically for single-cell SNV detection by filtering out potential artifacts due to whole-genome amplification (Methods) 3 . Germline variants were filtered out using the bulk DNAs of the same donors. Using Sanger sequencing, we confirmed 62 of 65 (95.4%) mutations randomly selected, indicating the high specificity of the variant calls ( Supplementary Fig. 3 and Supplementary Table 2 ). Because all somatic SNVs should be heterozygous due to the extremely low chance that mutations occur at the exact same site on both alleles, heterozygous germline SNP calling in the same cell is a good control for measuring sensitivity, which appeared to be on average 60% ( Supplementary Table 3 ; Methods). That is, 60% of the heterozygous SNPs identified in bulk DNA were also identified in a single cell. The less than 100% sensitivity is a consequence of the stringent filtering, which avoids false positives at the cost of occasionally missing a true variant.
After adjusting for genomic coverage and sensitivity, the numbers of SNVs per cell were estimated as between 237 and 5,862, with one extreme outlier of 11,765 (Figs. 1a, Supplementary  Table 3 ). The median number of mutations per cell was found to increase significantly with the age of the donor (P=3.93×10 -4 , Fig. 1a ), with on average 463.4 in the newborns (n=8 cells from two donors), 1,181.9 in the 27-30 year olds (n=8 cells from two donors), 2,101.7 in the 52-75 year olds (n=24 from 6 donors) and 3,127.0 in the 97-106 year olds (n=16 from 4 donors).
While virtually all mutations were unique for each cell, a total of 24 recurrent mutations, i.e., shared between cells, were identified. These recurrent mutations were only present in cells from the same donor, which was validated by Sanger sequencing of the recurrent mutations in all samples (Supplementary Fig. 4 and Supplementary Table 2 ). The cells that share mutations most likely derive from the same ancestor hematopoietic stem cell in which the mutation originally occurred. Of note, the recurrent mutations were mostly found in elderly donors (P=0.0115, permutation test, one-tailed, 20,000 permutations), which is in keeping with the observed decrease in the number of active lineages of hematopoietic stem cells during ageing 11 . However, the numbers of recurrent mutations were small and none occurred in the cancer driver genes used to identify clonal hematopoiesis of indeterminate potential (CHIP) 12 ; we also applied the same method as described in ref 12 and found that none of our 14 donors displayed CHIP (Methods).
While the observed increase in mutation frequency with age is in keeping with previous data on other cell types in both humans and mice [13] [14] [15] [16] [17] , accurate numbers obtained by single-cell sequencing are sparse and have not been thoroughly validated 6 . In terms of validation, B lymphocytes offer the advantage of endogenous control loci in the form of mutational hotspots at immunoglobulin genes 18 . After pooling all mutations of the 56 cells the large majority of mutations distributed randomly across the genome ( Supplementary Fig. 5a -c). However, we noticed already at Mb level a substantial enrichment of mutations at one end of chromosome 14 ( Supplementary  Fig. 5b ,c), which harbors immunoglobulin gene sequences 18 . At the kilobase (kb) level, we identified 24 mutational hotspots, defined as regions with multiple mutations separated by less than 5 kb from their nearest neighbor (using the "shower" algorithm; Fig. 1b , Supplementary Table  4 ; Methods) [19] [20] [21] . The 24 mutational hotspots are composed of 4 to 12 mutations in regions of 469 to 8,970 bp corresponding to a mutation frequency of 2.79x10 -3 per bp per cell in agreement with previous findings as determined from cloned, PCR-amplified target regions 22, 23 ; the average genome-wide mutation frequency is only about 10 -7 per bp.
Of the 24 hotspots ( Supplementary Fig. 6 ), only 5 were located in or close to immunoglobulin gene regions, i.e., 3 hotspots in the immunoglobulin H chain (IGH) region on chromosome 14 (Fig. 1c) , one in the immunoglobulin L (IGL) chain region and one other downstream of this region on chromosome 22 ( Supplementary Fig. 7 ). The other 19 hotspots are likely off-target effects of activation-induced cytidine deaminase (AID) 18 , the enzyme that initiates somatic hypermutation (SHM). Some of these hotspots have been described previously by others, such as BCL6 (B-cell CLL/lymphoma 6) 24 and BCL7A (BCL tumor suppressor 7A) 25 . To our knowledge, nobody has as yet demonstrated B lymphocyte mutational hotspots collectively across a single genome. However, when comparing to a mouse AID (mAID) ChIP sequencing dataset 26 , we found substantial overlap of the hotspot regions we identified with genes in the mAID dataset (odds ratio=1.93; Supplementary Fig. 8 ). While not significant (P=0.134, one tailed Fisher's exact test) this finding contributes to the notion that the hotspots we found are AID off-targets. Indeed, this conclusion is strengthened by the fact that about half of the 24 hotspots have been reported in other studies as associated with human lymphoma, leukemia, or AID off-target loci in mouse B cells 24, 25, [27] [28] [29] [30] [31] (Supplementary Table 4 ). Moreover, the hotspots significantly overlap with or are close to open chromatin regions, transcription start sites (TSS), and transcription factor (TF) binding sites associated with AID binding (Supplementary Table 4 ; Methods).
Based on the presence or absence of mutations in the 5 immunoglobulin hotspots we distinguished SHM + from SHMcells. In addition to SHM, we also identified class switch recombination (CSR) in some B cells, allowing to distinguish memory B cells (SHM + and CSR + ) from the SHM -/CSR -, naï ve B cells ( Fig. 1d , Supplementary Fig. 9 ; Methods). Of note, the SHM + cells had a significantly higher mutation frequency than the SHMcells (P=5.19x10 -5 , Supplementary Fig. 10a ). A significant age-related increase of mutations in both cell types was observed when analyzing all cells together with both ageing and SHM as variables (P=3.07x10 -4 for ageing, Supplementary Fig. 10a ). An age-related increase is also statistically significant when testing SHMcells alone, with ageing as the only variable (P=1.08x10 -4 , Supplementary Fig. 10b ).
Next, we analyzed the mutation spectra. In addition to the affected base ( Supplementary  Fig. 11a, b ; Methods), we also included their two flanking bases in the analysis. This allowed us to comparatively analyze mutation spectra as a function of age and SHM status. The results were compared to the spectrum we previously obtained for human fibroblasts 3 ( Supplementary Fig. 11c ). By using non-negative matrix factorization (NMF) 20, 32 , we decomposed the mutation spectra into mutation signatures, i.e., signatures A to D (Figs. 2a, b; Methods). Based on these signatures, we were able to, first, show that somatic mutations in B lymphocytes (Signatures A, B and D) are substantially different from those in fibroblasts (Signature C). Second, we were able to identify mutations specifically associated with development (Signature A), ageing (Signature B; P=9.25x10 -4 with age, Supplementary Fig. 12 ) and SHM (Signature D).
Importantly, these signatures observed in normal B lymphocytes from healthy human donors were very similar to mutation signatures obtained from human cancers, i.e. Catalogue Of Somatic Mutations in Cancer (COSMIC; Supplementary Fig. 11d) 4, 33, 34 . Our ageing signature B was found to correlate highly with the cancer ageing signatures COSMIC1 and COSMIC5 in many cancer types (Spearman's correlation coefficients ρ=0.80 and 0.74 separately, Fig. 2c , and Supplementary Fig. 11d ). Our developmental signature A also correlates to COSMIC1 (ρ=0.78), as does signature B. These results suggest that the mechanistic origin of these signatures, even in tumors firmly resides in the normal process of age-related mutation accumulation.
The "ageing signature" appeared mostly a result of spontaneous cytosine deamination 35 . The latter was also observed in the mutation signature of a childhood cancer, pilocytic astrocytoma (COSMIC19), resulting in a high correlation, ρ=0.81, with our signature B ( Supplementary Fig.  11d ). We also observed a high correlation between the SHM signature D and the chronic lymphocytic leukemia and malignant B-cell lymphoma signature COSMIC9 (ρ=0.81, Fig. 2d ). These results were confirmed by refitting the known COSMIC signatures to the observed somatic mutations in normal B lymphocytes, using the "deconstructSigs" package in R 36 . That is, COSMIC9 was only found in SHM+ cells and COSMIC5 and COSMIC19 were found in all cells ( Supplementary Fig. 13 ). Together with the observation of off-target SHM hotspots, these results strongly support the hypothesis that somatic hypermutation contributes significantly to the development of B cell cancers 18 . No significant difference was found between the genome-wide mutation signatures and those in the 24 hotspot areas ( Supplementary Fig. 14 Fig. 2a and Supplementary Fig. 13 ).
in comparison with
An important question we were now able to directly address for the first time is whether somatic mutation accumulation during ageing can have a functional impact other than increasing cancer risk. For this purpose we subdivided all mutations into two groups: those that were and those that were not found in the functional part of the genome. Mutations in the functional genome were defined as those occurring in the transcribed exome or its regulatory regions. To identify the transcribed exome we performed RNA-seq of purified, bulk B lymphocytes ( Supplementary Fig.  15 , Supplementary Table 5 ; Methods). As gene regulatory regions we considered both promoters of active genes and open chromatin regions, e.g., transcription factor (TF) binding regions, identified by ATAC-seq in the same bulk B cells ( Supplementary Fig. 16 , Supplementary Table 5 ; Methods).
Of the 9.2±6.8 nonsynonymous mutations on average per cell in the transcribed B cell exome of the ≥ 97-year olds ( Table 1 ; Supplementary Table 6 ), 6.5±5.5 (71%) were functionally deleterious according to SIFT and PROVEAN (Supplementary Table 7 ) 37, 38 . Many more potentially functional mutations occurred in noncoding regions of the genome (Table 1 , Supplementary Table 6 ). When analyzing the TF-binding regions reported by ENCODE 39 in our B lymphocytes, the number of mutations in these regions were found to increase with age from 79.6 to 435.9 on average per cell (P=8.79×10 -6 ). More specifically, when analyzing our own ATAC data, specific for B lymphocytes, we found an almost 5-fold age-related increase in the number of mutations in active open chromatin regions (likely to be TF-binding regions specific in B cells), from 5.4 to 24.5 per cell (P=0.0199). Even more mutations were found collectively in proximate promoter (from -1500 to +500bp of TSS), 5' UTR and 3' UTR regions, i.e., 56.9±26.9, 4.9±5.7 and 13.6±6.5, respectively, per cell in the oldest subjects. Hence, in the functional part of the B cell genome mutations were found to increase from 27.0±18.3 per cell in cells from newborns to 85.1±36.9 per cell in cells from >97 year olds (P=0.000878, exponential model non-linear least squares regression).
Next, we tested if mutations in the functional genome were also functionally impactful. To do that we compared the pace of age-related accumulation of mutations in the functional genome with that of mutations in the genome overall. The results indicated a highly significant slower pace of potentially functional mutations (P=1.42×10 -14 , Fig. 3 ). In this case we used all protein-coding genes since we could not ascertain the origin of the mutations, which could have been in hematopoietic stem cells with other genes active than the mature B lymphocytes. These results indicate protection against deleterious mutations in the functional genome during human ageing, suggesting that many random somatic mutations are damaging to cellular function.
The significantly lower rate of mutation accumulation in functional genomic regions than the genome-wide average suggests that the B cells and their ancestral stem cells that harbored such mutations may have died or been at a growth disadvantage. This is in keeping with the discovery of a decreased number of lymphoid hematopoietic lineages during ageing 11 and may underlie the CHIP phenomenon found in a fraction of elderly 40 . However, our data show that many mutations in the functional genome remain and continue to accumulate. While not lethal, such mutations may still contribute to the well-documented age-related decline in function that has been observed for many cell types in humans and experimental animals. As we and others have reported previously this effect may be mediated by increased cell-to-cell transcriptional variability [41] [42] [43] .
In summary, this first, comprehensive characterization of the landscape of somatic mutations in B lymphocytes across the entire human age range shows a highly significant agerelated increase of mutations. Mutation signatures in these normal B cells, which were significantly different from those in human primary fibroblasts 3 , were found to correlate with those previously observed in human cancers, most notably B cell leukemia. This finding underscores the increasing realization that age is the most important risk factor for cancer. A substantial fraction of all mutations were found to occur in sequence features functionally active in B lymphocytes. These mutations were actively selected against as evidenced by their much slower rate of accumulation with age. Hence, somatic mutations may contribute to functional decline in ageing through depletion of cells or accumulation of cells with slightly deleterious mutations. Of note, in this study we only analyzed base substitution mutations. Other types of mutations such as small INDELS or genome structural variation are much less frequent, but may still contribute to a gradual age-related deterioration of the functional somatic genome. In principle we could test for such mutations in our single-cell whole-genome sequences. Reliable computational tools for that purpose, equally sensitive and accurate as our current tool for base substitutions are currently under development. Our present results provide the foundation for finally testing the somatic mutation theory of ageing by studying multiple human organs and tissues for the accumulation of potentially functional mutations and their causal relationship to age-related functional decline and disease. 
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